Form 4: DXCM director reports 7,166 RSUs with three-year vesting

Rhea-AI Filing Summary

Dexcom, Inc. (DXCM) reported that director Euan Ashley acquired 7,166 restricted stock units on 10/24/2025 via a Form 4 filing.

The RSU grant was recorded at a $0 price and is scheduled to vest in three equal annual installments from the grant date. Following this transaction, the reporting person beneficially owned 7,166 shares, held with direct ownership.

Insights

Corporate governance analyst

Routine director RSU grant; minimal immediate impact.

The filing records a standard equity compensation event: 7,166 RSUs granted to a Dexcom director on 10/24/2025 at $0. RSUs align director incentives with shareholder value and do not involve cash outlay.

Vesting in three equal annual installments spreads recognition over time, typical for director awards. Dilution impact from this single grant is likely immaterial, and no sale occurred. Key details include 7,166 shares beneficially owned after the grant, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashley Euan A.

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/24/2025		A		7,166(1)	A	$0	7,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Euan Ashley	10/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dexcom (DXCM) disclose in this Form 4?

A director, Euan Ashley, acquired 7,166 restricted stock units on 10/24/2025.

How many RSUs were granted to the Dexcom (DXCM) director and at what price?

The grant was for 7,166 RSUs at a recorded price of $0.

What is the vesting schedule for the Dexcom (DXCM) RSUs?

The RSUs vest in three equal annual installments from the grant date.

How many shares does the reporting person own after the transaction?

Beneficial ownership after the transaction is 7,166 shares.

What is the ownership form reported for these Dexcom (DXCM) securities?

The ownership form is Direct (D).

What security type is involved in the Dexcom (DXCM) Form 4?

Restricted stock units that represent a right to receive one share of common stock per unit.